<DOC>
	<DOCNO>NCT01325558</DOCNO>
	<brief_summary>This Phase I , open-label , multi-center , competitive enrollment dose-escalation study ALT-836 combination standard care gemcitabine participant locally advance metastatic solid tumor . The purpose study determine maximum tolerate dose ( MTD ) , assess safety pharmacokinetic profile ALT-836 give gemcitabine . The clinical benefit , progression-free survival overall survival study participant also assess .</brief_summary>
	<brief_title>A Study ALT-836 Combination With Gemcitabine Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>Tissue Factor ( TF ) over-expressed cancer type . Results many recent study suggest key role TF development cancer-associated thrombosis , tumor growth , tumor angiogenesis , tumor metastasis . ALT-836 , recombinant human-chimeric monoclonal antibody , design direct TF antagonist block TF display cancer inhibit cancer-associated venous thromboembolism , tumor growth , tumor angiogenesis tumor metastasis . In numerous pre-clinical study laboratory animal , include non-human primate , ALT-836 exhibit potent anti-tumor , anti-thrombotic anti-inflammatory activity remarkable safety profile . In human , ALT-836 , administer single bolus monotherapy patient coronary artery disease ( CAD ) acute lung injury/acute respiratory distress syndrome ( ALI/ARDS ) , safe exhibit anti-coagulant anti-inflammatory effect . A Phase II study use multi-dose regimen ALT-836 conduct patient ALI/ARDS . In dose-escalation study describe protocol , investigator assess safety determine maximum tolerate dose ( MTD ) ALT-836 combination gemcitabine patient advanced malignancy know overexpress TF venous thromboembolism major complication .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm Locally advance metastatic nonhematologic malignancy Measureable Refractory standard therapy single agent gemcitabine indicated standard treatment option PRIOR/CONCURRENT THERAPY : No concurrent radiotherapy , chemotherapy , immunotherapy investigational agent Must recover side effect prior therapy PATIENT CHARACTERISTICS : Life expectancy &gt; 12 week Performance Status ECOG 0 1 Bone Marrow Reserve Absolute Neutrophil count ( AGC/ANC ) ≥ 1,500/uL Platelets ≥ 100,000/uL Hemoglobin &gt; 9 g/dL Renal Function Calculated Glomerular filtration rate ( GFR ) &gt; 59mL/min/1.73M^2 Hepatic Function Total bilirubin ≤ 1.5 X ULN AST , ALT , ALP ≤ 3 X ULN ≤ 5.0 x ULN , liver metastasis exist PT INR ≤ 1.5 X ULN Cardiovascular No history clinically significant vascular disease No New York Heart Association ( NYHA ) Class &gt; II heart failure Hematologic No history bleed disorder No evidence bleed diathesis coagulopathy No presence clinically significant hemoptysis hematuria , presence serious nonhealing wound ulceration , sign bleed No evidence tumor invasion major blood vessel No trauma increase risk lifethreatening bleed history severe head trauma intracranial surgery within two month study entry Surgery/Procedures No major surgery open biopsy within 28 day drug infusion evidence active bleeding postoperatively No plan major surgery treatment period No presence requirement epidural catheter lumbar puncture within 48 hour prior dose study treatment No anticipation receive epidural catheter lumbar puncture within 48 hour dose study treatment Excluded Medications Treatment Regimens Unfractionated heparin &gt; 15,000 units/day within 8 hour prior dose study treatment Lowmolecular weight heparin high dose recommend prophylactic use require within 20 hour prior dose study treatment Warfarin use require within 48 hour prior dose study treatment prothrombin time ( INR ) exceed upper limit normal range Direct thrombin inhibitor Xa inhibitor Acetylsalicylic acid use require within 72 hour prior dose study treatment Clopidogrel bisulfate use require within 48 hour prior dose study treatment Anticipated requirement antiplatelet anticoagulant agent exclude nonaspirin NSAID within 48 hour follow study treatment infusion Other No active systemic infection require parenteral antibiotic therapy No history presence CNS disease No history allergic reaction compound similar chemical biologic composition Not HIV positive No woman pregnant nurse A negative serum pregnancy test female Patients , female male , reproductive potential must agree use effective contraceptive measure duration study No history significant renal , endocrinologic , metabolic , immunologic hepatic disease No evidence psychiatric illness/social situation Other illness opinion investigator would exclude patient participate Must provide informed consent HIPAA authorization comply protocolspecified procedure followup evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>tissue factor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>colon cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>soft-tissue sarcoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>anti-tumor</keyword>
	<keyword>venous thromboembolism</keyword>
</DOC>